Byrne LK, Pan L, McCABE M, Mellor D, Xu Y Assessment of a six-week computer-based remediation program for social cognition in chronic schizophrenia. Shanghai Arch Psychiatry. 2015 Oct;27(5):296-306. doi: 10.11919/j.issn.1002-0829.215095.
Cohen AS, Minor KS Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr Bull. 2010 Jan;36(1):143-50. doi: 10.1093/schbul/sbn061. Epub 2008 Jun 17.
Combs DR, Chapman D, Waguspack J, Basso MR, Penn DL Attention shaping as a means to improve emotion perception deficits in outpatients with schizophrenia and impaired controls. Schizophr Res. 2011 Apr;127(1-3):151-6. doi: 10.1016/j.schres.2010.05.011. Epub 2010 Jun 8.
Combs DR, Tosheva A, Penn DL, Basso MR, Wanner JL, Laib K Attentional-shaping as a means to improve emotion perception deficits in schizophrenia. Schizophr Res. 2008 Oct;105(1-3):68-77. doi: 10.1016/j.schres.2008.05.018. Epub 2008 Jun 27.
Drusch K, Stroth S, Kamp D, Frommann N, Wölwer W Effects of Training of Affect Recognition on the recognition and visual exploration of emotional faces in schizophrenia. Schizophr Res. 2014 Nov;159(2-3):485-90. doi: 10.1016/j.schres.2014.09.003. Epub 2014 Sep 20.
Gaudelus B, Virgile J, Geliot S; GAÏA/RECOS Study Team, Franck N Improving Facial Emotion Recognition in Schizophrenia: a Controlled Study Comparing Specific and Attentional Focused Cognitive Remediation. Front Psychiatry. 2016 Jun 21;7:105. doi: 10.3389/fpsyt.2016.00105. eCollection 2016.
Gur RC, Gur RE Social cognition as an RDoC domain. Am J Med Genet B Neuropsychiatr Genet. 2016 Jan;171B(1):132-41. doi: 10.1002/ajmg.b.32394. Epub 2015 Nov 26. Review.
Hooker CI, Bruce L, Fisher M, Verosky SC, Miyakawa A, Vinogradov S Neural activity during emotion recognition after combined cognitive plus social cognitive training in schizophrenia. Schizophr Res. 2012 Aug;139(1-3):53-9. doi: 10.1016/j.schres.2012.05.009. Epub 2012 Jun 12.
Huang CL, Hsiao S The Functional Significance of Affect Recognition, Neurocognition, and Clinical Symptoms in Schizophrenia. PLoS One. 2017 Jan 18;12(1):e0170114. doi: 10.1371/journal.pone.0170114. eCollection 2017.
Kerr SL, Neale JM Emotion perception in schizophrenia: specific deficit or further evidence of generalized poor performance? J Abnorm Psychol. 1993 May;102(2):312-8.
Kring AM, Elis O Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol. 2013;9:409-33. doi: 10.1146/annurev-clinpsy-050212-185538. Epub 2012 Dec 10. Review.
Marsh PJ, Luckett G, Russell T, Coltheart M, Green MJ Effects of facial emotion recognition remediation on visual scanning of novel face stimuli. Schizophr Res. 2012 Nov;141(2-3):234-40. doi: 10.1016/j.schres.2012.08.006. Epub 2012 Sep 5.
Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000 Apr;101(4):323-9.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
